Qureator is proud to announce that we have been selected as a Phase 1 Winner in the NIH Common Fund’s Complement-ARIE Reduction to Practice Challenge. Our winning proposal, “Combining vTIME and AI for IO Drug CRS Prediction,” was recognized among 20 innovative projects advancing human-based New Approach Methodologies (NAMs) to improve biomedical research and reduce reliance on animal models.
This recognition validates Qureator’s commitment to transforming immuno-oncology drug development through the integration of our vTIME platform with advanced artificial intelligence to predict cytokine release syndrome (CRS) and enhance the safety assessment of novel therapies. We are honored to be part of this distinguished group of innovators and look forward to advancing into Phase 2, where we will continue refining our technology toward practical implementation. We thank the NIH Common Fund and the Complement-ARIE program for supporting innovations that accelerate more predictive, human-relevant biomedical research.